Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma. (December 2015)

• Record Type: Journal Article
• Authors: Chen, Yen-Hao; Huang, Cheng-Hua; Lu, Hung-I; Chen, Chang-Han; Huang, Wan-Ting; Hsieh, Ming-Jang; Rau, Kun-Ming; Chang, Alice YW; Lin, Wei-Che; Li, Shau-Hsuan
• Is Part Of: Journal of the renin-angiotensin-aldosterone system. Volume 16:Number 4(2015:Dec.)
• Page Start: 1185
• Page End: 1192
• Publication Date: 2015-12
• Subjects: Esophageal cancer -- squamous cell carcinoma -- angiotensin I-converting enzyme inhibitors -- angiotensin II type 1 receptor blockers -- renin-angiotensin system; Renin-angiotensin system -- Periodicals; 616.132
• DOI: 10.1177/1470320314535275
• Languages: English
• ISSNs: 1470-3203

Abstract

Introduction: The aim of this study is to evaluate whether the administration of renin-angiotensin system (RAS) inhibitors, angiotensin-I converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), is associated with treatment outcome in patients with esophageal squamous cell carcinoma. Materials and methods: A total of 141 esophageal squamous cell carcinoma patients receiving esophagectomy were identified, and were divided into two groups: an ACEI/ARB group ( n =20), and a non-ACEI/ARB group ( n =121). The effect of ACEIs or ARBs on cell proliferation and vascular endothelial growth factor (VEGF) secretion of esophageal squamous cell carcinoma cell lines, CE81T/VGH and TE2, were investigated by 3-(4.5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay and Enzyme-linked immunosorbent assay (ELISA), respectively. Results: Use of ACEI/ARB ( p =0.032), pathologic T stage ( p <0.001), pathologic N stage ( p =0.012), tumor stage ( p =0.006), and tumor location ( p =0.032) were significantly associated with superior overall survival. In multivariate comparison, use of ACEI/ARB ( p =0.006), tumor stage ( p =0.002), and tumor location ( p =0.014) represented the independent prognosticators of superior overall survival. In cell lines, ACEIs/ARBs inhibit cell proliferation and VEGF secretion in a dose-dependent manner. Conclusions: ACEIs/ARBs administration is independently associated with superior overall survival in patients with esophageal squamous cell carcinoma receiving esophagectomy. Our data support further investigation of the role of RAS inhibitors as a potential therapy in esophageal squamous cell carcinoma.